Figure 1. Patient flow diagram

Screened 5,868 febrile patients

Malaria +ve = 1,310 (22%)

P. falciparum 1,223 (93.3%)
Mixed (Pf+Pv = 15; Pf+Pm = 1) 16 (1.2%)

609 P. falciparum + mixed infection patients excluded from the trial of thiamin treatment and P. falciparum in Laos: low probability of completing follow-up (75%), unwillingness to consent to the study (25%)

630 enrolled in the trial of thiamin treatment

Thiamin 314
Withdrawal of consent for further follow up = 4 and early termination due to repeated vomiting= 1
Completed 42-day follow up 309 (98%)

P. falciparum reappeared during follow up = 20 (6%). By PCR, 14 were new infections, 6 were recrudescence

Placebo 316
Withdrawal of consent for further follow up = 3 and early termination due to repeated vomiting=1
Completed 42-day follow up 308 (97%)

P. falciparum reappeared during follow up = 30 (9%). By PCR, 18 were new infections, 11 were recrudescence and 1 was undetermined

N.B. +ve = positive; Pf = Plasmodium falciparum; Pv = P. vivax; Pm = P. malariae; PCR = polymerase chain reaction.